Isosorbide Dinitrate Dosing
For oral maintenance therapy, start isosorbide dinitrate at 5-20 mg two to three times daily and titrate to 10-40 mg two to three times daily, ensuring a 14-hour nitrate-free interval to prevent tolerance. 1234
Oral Dosing Regimens
Immediate-Release Formulation
- Starting dose: 5-20 mg, 2-3 times daily 1234
- Maintenance dose: 10-40 mg, 2-3 times daily 123
- Maximum dose: Up to 80 mg per dose, 2-3 times daily (some patients may require higher doses) 123
- Duration of effect: Up to 8 hours 123
Slow-Release Formulation
Critical Dosing Principle: Nitrate-Free Interval
You must provide at least a 14-hour daily nitrate-free interval to prevent tolerance development. 134 This is non-negotiable—continuous 24-hour nitrate therapy leads to refractory tolerance within 24 hours, rendering the medication ineffective. 13
A practical regimen would be dosing at 0800,1400, and 1800 hours, providing the overnight nitrate-free period. 13
Intravenous Dosing (Not Standard for Isosorbide Dinitrate)
Important caveat: The guidelines primarily describe nitroglycerin for IV use, not isosorbide dinitrate. 123 However, when IV isosorbide dinitrate is used:
- Initial dose: 1-10 mg/hour 56
- Bolus administration: 5-10 mg IV bolus has been studied in acute settings 78
- Continuous infusion: 5.0-7.5 mg/hour for heart failure 9
Research shows IV bolus of 5-10 mg isosorbide dinitrate can effectively treat acute cardiogenic pulmonary edema, with blood pressure decreasing approximately 19% systolic and 16% diastolic. 7 For post-cardiac surgery hypertension, bolus doses of 0.25-2.5 mg (3-40 mcg/kg) or continuous infusion of 0.125-0.332 mg/min (1.5-6.0 mcg/kg/min) have been effective. 8
Heart Failure Specific Dosing (Hydralazine-Isosorbide Dinitrate Combination)
For heart failure with reduced ejection fraction, particularly in self-identified Black patients or those intolerant to ACE inhibitors/ARBs:
Fixed-Dose Combination 101112
- Starting dose: 20 mg isosorbide dinitrate + 37.5 mg hydralazine, 3 times daily
- Target dose: 40 mg isosorbide dinitrate + 75 mg hydralazine, 3 times daily
- Mean dose achieved in trials: ~90 mg isosorbide dinitrate + ~175 mg hydralazine total daily 101112
Individual Components 101112
- Isosorbide dinitrate: 20-30 mg, 3-4 times daily, up to 120 mg total daily
- Hydralazine: 25-50 mg, 3-4 times daily, up to 300 mg total daily
This combination reduces mortality by 43% (NNT=25 over 10 months) in appropriate heart failure patients. 1112
Adjustments for Special Populations
Hypotension
- Avoid if systolic BP <90 mmHg 123
- If blood pressure drops below 90-100 mmHg during treatment, reduce dose or discontinue 5
- Titrate carefully in patients with baseline systolic BP 90-110 mmHg 6
Renal Impairment
No dose adjustment is required for renal insufficiency. 13 Pharmacokinetic studies show no correlation between drug accumulation and degree of renal impairment, making isosorbide dinitrate particularly useful in cardiorenal syndrome. 1314 This is a significant advantage over many other cardiovascular medications.
Elderly Patients
- Start at the lower end of the dosing range 15
- Isosorbide dinitrate may be eliminated more slowly 16
- Studies in patients ≥75 years show similar safety profile with careful titration 17
Common Pitfalls to Avoid
Tolerance development: The most critical error is failing to provide a nitrate-free interval. Without this, the drug becomes ineffective after 24 hours. 134
Phosphodiesterase inhibitor interaction: Absolute contraindication with sildenafil (24 hours), tadalafil (48 hours), or vardenafil. This combination can cause profound hypotension, MI, and death. 12316
Inadequate dosing: Many patients receive subtherapeutic doses. If tolerated, titrate to at least 10-40 mg per dose for maintenance. 4
Expecting >12 hours of anti-anginal effect: No dosing regimen provides more than approximately 12 hours of continuous efficacy per day. 144
Right ventricular infarction: Use extreme caution in inferior MI due to potential RV involvement—these patients are preload-dependent and can develop profound hypotension. 18